Increased hexokinase II expression in the renal glomerulus of mice in response to arsenic

Toxicology and Applied Pharmacology

Volumn 224, Issue 1, 2007, Pages 39-48

  Pysher, Michele D ^a   Sollome, James J ^a   Regan, Suzanne ^a   Cardinal, Trevor R ^b   Hoying, James B ^b   Brooks, Heddwen L ^c   Vaillancourt, Richard R ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b University of Arizona   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Arsenic; Arsenite; Hexokinase

Indexed keywords

ARSENIC; DRINKING WATER; HEXOKINASE; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GLOMERULUS; IN VITRO STUDY; IN VIVO STUDY; MALE; MESANGIUM CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; UPREGULATION;

ANIMALS; ARSENIC; CELL LINE; CELLS, CULTURED; FLUORESCENT ANTIBODY TECHNIQUE; GLOMERULAR MESANGIUM; HEXOKINASE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KIDNEY CORTEX; KIDNEY GLOMERULUS; MALE; MICE; MICE, INBRED C57BL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; UP-REGULATION; WATER;

MUS;

EID: 34548608765     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2007.06.019     Document Type: Article

References (48)

1. Anderson J.W., and Stowring L. Glycolytic and gluconeogenic enzyme-activities in renal cortex of diabetic rats. Am. J. Physiol. 224 (1973) 930-936
2. Arora K.K., and Pedersen P.L. Functional-significance of mitochondrial bound hexokinase in tumor-cell metabolism-Evidence for preferential phosphorylation of glucose by intramitochondrially generated ATP. J. Biol. Chem. 263 (1988) 17422-17428
3. Azoulay-Zohar H., Israelson A., Abu-Hamad S., and Shoshan-Barmatz V. In self-defence: hexokinase promotes voltage-dependent anion channel closure and prevents mitochondria-mediated apoptotic cell death. Biochem. J. 377 (2004) 347-355
4. Bates M.N., Rey O.A., Biggs M.L., Hopenhayn C., Moore L.E., Kalman D., Steinmaus C., and Smith A.H. Case-control study of bladder cancer and exposure to arsenic in Argentina. Am. J. Epidemiol. 159 (2004) 381-389
5. Bradford M.M. Rapid and sensitive method for quantitation of microgram quantities of protein utilizing principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
6. Bryson J.M., Coy P.E., Gottlob K., Hay N., and Robey R.B. Increased hexokinase activity, of either ectopic or endogenous origin, protects renal epithelial cells against acute oxidant-induced cell death. J. Biol. Chem. 277 (2002) 11392-11400
7. Burns F.J., Uddin A.N., Wu F., Nadas A., and Rossman T.G. Arsenic-induced enhancement of ultraviolet radiation carcinogenesis in mouse skin: a dose-response study. Environ. Health Perspect. 112 (2004) 599-603
8. Bustamante E., and Pedersen P.L. High aerobic glycolysis of rat hepatoma-cells in culture-Role of mitochondrial hexokinase-(l-lactic acid-d-glucose-d-galactose-liver-neoplasia). Proc. Natl. Acad. Sci. U.S.A. 74 (1977) 3735-3739
9. Bustamante E., and Pedersen P.L. Mitochondrial hexokinase of rat hepatoma-cells in culture-Solubilization and kinetic-properties. Biochemistry 19 (1980) 4972-4977
10. Bustamante E., Morris H.P., and Pedersen P.L. Energy-metabolism of tumor-cells-Requirement for a form of hexokinase with a propensity for mitochondrial binding. J. Biol. Chem. 256 (1981) 8699-8704
11. Centeno J.A., Mullick F.G., Martinez L., Page N.P., Gibb H., Longfellow D., Thompson C., and Ladich E.R. Pathology related to chronic arsenic exposure. Environ. Health Perspect. 110 (2002) 883-886
12. Chiu H.F., and Yang C.Y. Decreasing trend in renal disease mortality after cessation from arsenic exposure in a previous arseniasis-endemic area in southwestern Taiwan. J. Toxicol. Environ. Health, Part A 68 (2005) 319-327
13. Cui X., Li S., Shraim A., Kobayashi Y., Hayakawa T., Kanno S., Yamamoto M., and Hirano S. Subchronic exposure to arsenic through drinking water alters expression of cancer-related genes in rat liver. Toxicol. Pathol. 32 (2004) 64-72
14. Frumkin H., and Thun M.J. Arsenic. CA-Cancer J. Clin. 51 (2001) 254-262
15. Germolec D.R., Spalding J., Yu H.S., Chen G.S., Simeonova P.P., Humble M.C., Bruccoleri A., Boorman G.A., Foley J.F., Yoshida T., and Luster M.I. Arsenic enhancement of skin neoplasia by chronic stimulation of growth factors. Am. J. Pathol. 153 (1998) 1775-1785
16. Goering P.L., Aposhian H.V., Mass M.J., Cebrian M., Beck B.D., and Waalkes M.P. The enigma of arsenic carcinogenesis: role of metabolism. Toxicol. Sci. 49 (1999) 5-14
17. Gottlob K., Majewski N., Kennedy S., Kandel E., Robey R.B., and Hay N. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev. 15 (2001) 1406-1418
18. Haneda M., Koya D., Isono M., and Kikkawa R. Overview of glucose signaling in mesangial cells in diabetic nephropathy. J. Am. Soc. Nephrol. 14 (2003) 1374-1382
19. Hopenhayn-Rich C., Biggs M.L., and Smith A.H. Lung and kidney cancer mortality associated with arsenic in drinking water in Cordoba, Argentina. Int. J. Epidemiol. 27 (1998) 561-569
20. Katzen H.M., Soderman D.D., and Wiley C.E. Multiple forms of hexokinase-activities associated with subcellular particulate and soluble fractions of normal and streptozotocin diabetic rat tissues. J. Biol. Chem. 245 (1970) 4081
21. Kitchin K.T. Recent advances in arsenic carcinogenesis: modes of action, animal model systems, and methylated arsenic metabolites. Toxicol. Appl. Pharmacol. 172 (2001) 249-261
22. Lee M.G., and Pedersen P.L. Glucose metabolism in cancer-Importance of transcription factor-DNA interactions within a short segment of the proximal region of the type II hexokinase promoter. J. Biol. Chem. 278 (2003) 41047-41058
23. Lu T., Liu J., LeCluyse E.L., Zhou Y.S., Cheng M.L., and Waalkes M.P. Application of cDNA microarray to the study of arsenic-induced liver diseases in the population of Guizhou, China. Toxicol. Sci. 59 (2001) 185-192
24. Majewski N., Nogueira V., Robey R.B., and Hay N. Akt inhibits apoptosis downstream of BID cleavage via a glucose-dependent mechanism involving mitochondrial hexokinases. Mol. Cell. Biol. 24 (2004) 730-740
25. Mason R.M., and Wahab N.A. Extracellular matrix metabolism in diabetic nephropathy. J. Am. Soc. Nephrol. 14 (2003) 1358-1373
26. Mass M.J., Tennant A., Roop B.C., Cullen W.R., Styblo M., Thomas D.J., and Kligerman A.D. Methylated trivalent arsenic species are genotoxic. Chem. Res. Toxicol. 14 (2001) 355-361
27. Okoji R.S., Yu R.C., Maronpot R.R., and Froines J.R. Sodium arsenite administration via drinking water increases genome-wide and Ha-ras DNA hypomethylation in methyl-deficient C57BL/6J mice. Carcinogenesis 23 (2002) 777-785
28. Parry D.M., and Pedersen P.L. Intracellular-localization of rat-kidney hexokinase-Evidence for an association with low-density mitochondria. J. Biol. Chem. 259 (1984) 8917-8923
29. Pastorino J.G., Shulga N., and Hoek J.B. Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis. J. Biol. Chem. 277 (2002) 7610-7618
30. Pedersen P.L., Mathupala S., Rempel A., Geschwind J.F., and Ko Y.H. Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim. Biophys. Acta, Bioenerg. 1555 (2002) 14-20
31. Ratnaike R.N. Acute and chronic arsenic toxicity. Postgrad. Med. J. 79 (2003) 391-396
32. Rea M.A., Gregg J.P., Qin Q., Phillips M.A., and Rice R.H. Global alteration of gene expression in human keratinocytes by inorganic arsenic. Carcinogenesis 24 (2003) 747-756
33. Robey R.B., Raval B.J., Ma J.F., and Santos A.V.P. Thrombin is a novel regulator of hexokinase activity in mesangial cells. Kidney Int. 57 (2000) 2308-2318
34. Robey R.B., Ma J.F., Santos A.V.P., Noboa O.A., Coy P.E., and Bryson J.M. Regulation of mesangial cell hexokinase activity and expression by heparin-binding epidermal growth factor-like growth factor-Epidermal growth factors and phorbol esters increase glucose metabolism via a common mechanism involving classic mitogen-activated protein kinase pathway activation and induction of hexokinase II expression. J. Biol. Chem. 277 (2002) 14370-14378
35. Rossman T.G., Uddin A.N., Burns F.J., and Bosland M.C. Arsenite is a cocarcinogen with solar ultraviolet radiation for mouse skin: An animal model for arsenic carcinogenesis. Toxicol. Appl. Pharmacol. 176 (2001) 64-71
36. Schlondorff D. The glomerular mesangial cell-An expanding role for a specialized pericyte. FASEB J. 1 (1987) 272-281
37. Schoen A., Beck B., Sharma R., and Dube E. Arsenic toxicity at low doses: epidemiological and mode of action considerations. Toxicol. Appl. Pharmacol. 198 (2004) 253-267
38. Simeonova P.P., and Luster M.I. Arsenic and atherosclerosis. Toxicol. Appl. Pharmacol. 198 (2004) 444-449
39. Simeonova P.P., Wang S.Y., Toriuma W., Kommineni V., Matheson J., Unimye N., Kayama F., Harki D., Ding M., Vallyathan V., and Luster M.I. Arsenic mediates cell proliferation and gene expression in the bladder epithelium: association with activating protein-1 transactivation. Cancer Res. 60 (2000) 3445-3453
40. Steer K.A., Sochor M., Gonzalez A.M., and McLean P. Regulation of pathways of glucose-metabolism in kidney-Specific linking of pentose-phosphate pathway activity with kidney growth in experimental diabetes and unilateral nephrectomy. FEBS Lett. 150 (1982) 494-498
41. Styblo M., Drobna Z., Jaspers I., Lin S., and Thomas D.J. The role of biomethylation in toxicity and carcinogenicity of arsenic: a research update. Environ. Health Perspect. 110 (2002) 767-771
42. Sun G.F. Arsenic contamination and arsenicosis in China. Toxicol. Appl. Pharmacol. 198 (2004) 268-271
43. Tseng C.H. The potential biological mechanisms of arsenic-induced diabetes mellitus. Toxicol. Appl. Pharmacol. 197 (2004) 67-83
44. Tseng C.H., Chong C.K., Heng L.T., Tseng C.P., and Tai T.Y. The incidence of type 2 diabetes mellitus in Taiwan. Diabetes Res. Clin. Pract. 50 (2000) S61-S64
45. Tseng C.H., Tai T.Y., Chong C.K., Tseng C.P., Lai M.S., Lin B.J., Chiou H.Y., Hsueh Y.M., Hsu K.H., and Chen C.J. Long-term arsenic exposure and incidence of non-insulin-dependent diabetes mellitus: a cohort study in arseniasis-hyperendemic villages in Taiwan. Environ. Health Perspect. 108 (2000) 847-851
46. Wauson E.M., Langan A.S., and Vorce R.L. Sodium arsenite inhibits and reverses expression of adipogenic and fat cell-specific genes during in vitro adipogenesis. Toxicol. Sci. 65 (2002) 211-219
47. Whiteside C.I., and Dlugosz J.A. Mesangial cell protein kinase C isozyme activation in the diabetic milieu. Am. J. Physiol.: Renal Physiol. 282 (2002) F975-F980
48. Yoshida T., Yamauchi H., and Sun G.F. Chronic health effects in people exposed to arsenic via the drinking water: dose-response relationships in review. Toxicol. Appl. Pharmacol. 198 (2004) 243-252